- Home
- BRTX
as 10-29-2025 4:00pm EST
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MELVILLE |
| Market Cap: | 12.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 325.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.19 - $2.55 | Next Earning Date: | 11-13-2025 |
| Revenue: | $605,200 | Revenue Growth: | 247.62% |
| Revenue Growth (this year): | 232.67% | Revenue Growth (next year): | 52.92% |
Latest BioRestorative Therapies Inc. (NV) News
BRTX Breaking Stock News: Dive into BRTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
GlobeNewswire
14 days ago
BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
GlobeNewswire
22 days ago
BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”
GlobeNewswire
23 days ago
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
GuruFocus.com
3 months ago
BioRestorative Therapies Inc (BRTX) Q2 2025 Earnings Call Highlights: Revenue Surge Amid ...
Zacks
3 months ago
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates
GlobeNewswire
3 months ago
BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
4 months ago
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates
Compare BRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BRTX BioRestorative Therapies Inc. (NV) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.